Levodopa-Carbidopa Intestinal Gel Infusion System
The brand name of the levodopa-carbidopa intestinal gel infusion system for Parkinson's disease is DUOPA (marketed by AbbVie). 1
Product Details
DUOPA is the FDA-approved brand name for carbidopa and levodopa enteral suspension delivered via continuous intrajejunal infusion. The formulation contains 4.63 mg/mL of carbidopa (anhydrous) and 20 mg/mL of levodopa 1.
Delivery System Components
The therapy utilizes:
- CADD-Legacy pump (manufactured by Smiths Medical ASD, Inc.) for continuous delivery 1
- Percutaneous endoscopic gastrostomy with jejunal tube (PEG-J) placement
- Medication cassette reservoirs (100 mL capacity) 1
Alternative Terminology
In clinical literature and international markets, this same therapy is also referred to as:
- LCIG (levodopa-carbidopa intestinal gel) 2
- Duodopa (the European brand name, also by Abbott/AbbVie) 3, 4, 5, 6
Recent Development
A newer formulation called LECIG (levodopa-entacapone-carbidopa intestinal gel) has been approved in Europe, which adds entacapone to enhance levodopa bioavailability 7, 8. This represents an evolution of the original DUOPA/Duodopa formulation.
Evidence Base
DUOPA/LCIG has Level 2 evidence supporting its use in advanced Parkinson's disease with motor fluctuations, based on 2 randomized controlled trials 2. The 2024 European Academy of Neurology/Movement Disorder Society guidelines rank it third in evidence strength among invasive therapies for Parkinson's disease, after subthalamic nucleus deep brain stimulation and globus pallidus interna stimulation 2.